Literature DB >> 23998732

CD4 T-cell immunotherapy for chronic viral infections and cancer.

Alice O Kamphorst1, Rafi Ahmed.   

Abstract

During chronic infections and cancer, T cells progressively lose function and become exhausted. However, effective T-cell responses are necessary to ultimately control viral infections and tumors. Hence, strategies that either restore endogenous immune responses or provide functional T cells by adoptive immunotherapy need to be explored. CD8 T cells play a prominent role in viral infections, as well as cancer, but CD4 T cells are necessary to support CD8 T-cell function. In addition, CD4 T cells exert direct effector functions, induce optimal B-cell responses and orchestrate innate immunity. Therefore, we propose that adoptive transfer strategies should exploit CD4 T cells alone or in combination with CD8 T cells, for the treatment of chronic infections and cancer. Furthermore, since adoptively transferred cells are subject to exhaustion, combining adoptive transfer therapy with immunotherapies that inhibit T-cell exhaustion should maximize the longevity and success rate of responses.

Entities:  

Mesh:

Year:  2013        PMID: 23998732      PMCID: PMC3864579          DOI: 10.2217/imt.13.91

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  96 in total

Review 1.  Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy.

Authors:  Deborah M Brown
Journal:  Cell Immunol       Date:  2010-02-24       Impact factor: 4.868

2.  Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter.

Authors:  Gabriel D Victora; Tanja A Schwickert; David R Fooksman; Alice O Kamphorst; Michael Meyer-Hermann; Michael L Dustin; Michel C Nussenzweig
Journal:  Cell       Date:  2010-11-12       Impact factor: 41.582

3.  HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function.

Authors:  Mathieu F Chevalier; Boris Jülg; Augustine Pyo; Michael Flanders; Srinika Ranasinghe; Damien Z Soghoian; Douglas S Kwon; Jenna Rychert; Jeffrey Lian; Matthias I Muller; Sam Cutler; Elizabeth McAndrew; Heiko Jessen; Florencia Pereyra; Eric S Rosenberg; Marcus Altfeld; Bruce D Walker; Hendrik Streeck
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

Review 4.  Redefining chronic viral infection.

Authors:  Herbert W Virgin; E John Wherry; Rafi Ahmed
Journal:  Cell       Date:  2009-07-10       Impact factor: 41.582

Review 5.  Follicular helper CD4 T cells (TFH).

Authors:  Shane Crotty
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

Review 6.  Monoclonal antibodies: versatile platforms for cancer immunotherapy.

Authors:  Louis M Weiner; Rishi Surana; Shangzi Wang
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

7.  Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Authors:  Helen E Heslop; Karen S Slobod; Martin A Pule; Gregory A Hale; Alexandra Rousseau; Colton A Smith; Catherine M Bollard; Hao Liu; Meng-Fen Wu; Richard J Rochester; Persis J Amrolia; Julia L Hurwitz; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

8.  IL-21R on T cells is critical for sustained functionality and control of chronic viral infection.

Authors:  Anja Fröhlich; Jan Kisielow; Iwana Schmitz; Stefan Freigang; Abdijapar T Shamshiev; Jacqueline Weber; Benjamin J Marsland; Annette Oxenius; Manfred Kopf
Journal:  Science       Date:  2009-05-28       Impact factor: 47.728

9.  Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.

Authors:  Florence R Depontieu; Jie Qian; Angela L Zarling; Tracee L McMiller; Theresa M Salay; Andrew Norris; A Michelle English; Jeffrey Shabanowitz; Victor H Engelhard; Donald F Hunt; Suzanne L Topalian
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-06       Impact factor: 11.205

10.  CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help.

Authors:  Yusuke Nakanishi; Bao Lu; Craig Gerard; Akiko Iwasaki
Journal:  Nature       Date:  2009-11-08       Impact factor: 49.962

View more
  27 in total

Review 1.  The elucidation of non-classical MHC class II antigen processing through the study of viral antigens.

Authors:  Asha Purnima Veerappan Ganesan; Laurence C Eisenlohr
Journal:  Curr Opin Virol       Date:  2017-01-12       Impact factor: 7.090

2.  Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells.

Authors:  Anthony Garnier; Mohamad Hamieh; Aurélie Drouet; Jérôme Leprince; Denis Vivien; Thierry Frébourg; Brigitte Le Mauff; Jean-Baptiste Latouche; Olivier Toutirais
Journal:  Immunol Cell Biol       Date:  2016-02-29       Impact factor: 5.126

3.  Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor.

Authors:  Hillary G Caruso; Hiroki Torikai; Ling Zhang; Sourindra Maiti; Jianliang Dai; Kim-Anh Do; Harjeet Singh; Helen Huls; Dean A Lee; Richard E Champlin; Amy B Heimberger; Laurence J N Cooper
Journal:  J Immunother       Date:  2016-06       Impact factor: 4.456

4.  Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials.

Authors:  David H McKenna; Darin Sumstad; Diane M Kadidlo; Bjorn Batdorf; Colin J Lord; Sarah C Merkel; Christine M Koellner; Julie M Curtsinger; Carl H June; James L Riley; Bruce L Levine; Jeffrey S Miller; Claudio G Brunstein; John E Wagner; Bruce R Blazar; Keli L Hippen
Journal:  Cytotherapy       Date:  2016-11-22       Impact factor: 5.414

Review 5.  Chimeric antigen receptor T-cell approaches to HIV cure.

Authors:  Anne-Sophie Kuhlmann; Christopher W Peterson; Hans-Peter Kiem
Journal:  Curr Opin HIV AIDS       Date:  2018-09       Impact factor: 4.283

6.  HIV-Specific T Cells Generated from Naive T Cells Suppress HIV In Vitro and Recognize Wide Epitope Breadths.

Authors:  Shabnum Patel; Elizabeth Chorvinsky; Shuroug Albihani; Conrad Russell Cruz; R Brad Jones; Elizabeth J Shpall; David M Margolis; Richard F Ambinder; Catherine M Bollard
Journal:  Mol Ther       Date:  2018-04-12       Impact factor: 11.454

7.  Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells.

Authors:  Haiyan S Li; Chengwen Liu; Yichuan Xiao; Fuliang Chu; Xiaoxuan Liang; Weiyi Peng; Jianhua Hu; Sattva S Neelapu; Shao-Cong Sun; Patrick Hwu; Stephanie S Watowich
Journal:  Sci Signal       Date:  2016-09-27       Impact factor: 8.192

Review 8.  T-cell therapies for HIV: Preclinical successes and current clinical strategies.

Authors:  Shabnum Patel; R Brad Jones; Douglas F Nixon; Catherine M Bollard
Journal:  Cytotherapy       Date:  2016-06-02       Impact factor: 5.414

9.  MiR-195 restrains lung adenocarcinoma by regulating CD4+ T cell activation via the CCDC88C/Wnt signaling pathway: a study based on the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) and bioinformatic analysis.

Authors:  Cheng Yuan; Liyang Xiang; Rui Bai; Kuo Cao; Yanping Gao; Xueping Jiang; Nannan Zhang; Yan Gong; Conghua Xie
Journal:  Ann Transl Med       Date:  2019-06

10.  Assay and Isolation of Single Proliferating CD4+ Lymphocytes Using an Automated Microraft Array Platform.

Authors:  Cody A LaBelle; Raymond J Zhang; Paul M Armistead; Nancy L Allbritton
Journal:  IEEE Trans Biomed Eng       Date:  2019-11-26       Impact factor: 4.538

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.